Accessing Continuous Glucose Monitoring (CGM) Sensors in France and the US
A Comparative Case Study of Abbott’s FreeStyle Libre (FSL) System
Blood sugar monitoring is at the heart of every type one diabetic’s treatment. Because patients need make 500,000 decisions over a lifetime on average, reliability on monitoring devices is vital. Thus, the development of Continuous Glucose Monitoring (CGM) systems came as a revolution, as patients need not prick their fingers anymore and now have access to previously unavailable blood sugar trends. This note uses Abbott’s FreeStyle Libre (FSL) as a CGM case study comparing the patenting strategies, regulatory and pricing obstacles this biotechnology company had to face to market its product in both France and the United States.
Unless specified by prior arrangement, the author agrees to the following terms and assurances:
- For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
- I/we further give to the following assurances
- I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
- I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
- To the best of my/our knowledge, all the facts in the contribution are true and accurate;
- The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
- Nothing in the contribution is obscene or libellous;
- Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
- I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).